AKT1 and central nervous system cancer: TH588 (a MutT homolog 1 (MTH1) inhibitor) and BKM120 (a pan-PI3K inhibitor) combined treatment promotes DNA damage and apoptosis by activating PI3K/AKT/mTOR in glioma cells [189].